A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low-, intermediate-, and high-risk groups: Reactivation risk is increased by graft-versus-host disease only in the intermediate-risk group

Transplant Infectious Disease

Volumn 14, Issue 2, 2012, Pages 141-148

  George, B ^a   Kerridge, I H ^a   Gilroy, N ^a   Huang, G ^a   Hertzberg, M S ^a   Bradstock, K F ^a   Gottlieb, D J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Allogeneic stem cell transplant; Cytomegalovirus; Graft versus host disease; Risk score

Indexed keywords

ALEMTUZUMAB; CORTICOSTEROID; THYMOCYTE ANTIBODY;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CALCULATION; CLINICAL DECISION MAKING; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; GRAFT VERSUS HOST REACTION; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; PATIENT MONITORING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; VALIDATION PROCESS; VIRUS REACTIVATION;

CYTOMEGALOVIRUS INFECTIONS; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RETROSPECTIVE STUDIES; RISK FACTORS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; VIRUS ACTIVATION;

EID: 84859846873     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2011.00706.x     Document Type: Article

References (21)

1. Osarogiagbon RU, Defor TE, Weisdorf MA, et al. CMV antigenemia following bone marrow transplantation: risk factors and outcomes. Biol Blood Marrow Transplant 2000; 6 (3): 280-288.
2. Ljungman P. CMV infections after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 42 (Suppl 1): S70-S72.
3. Hebart H, Jahn G, Sinzger C, et al. CMV infection in bone marrow and solid organ transplant patients in the era of antiviral prophylaxis. Herpes 2001; 7 (1): 13-17.
4. Zaia JA. Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation. Clin Infect Dis 2002; 35: 999-1004.
5. Boeckh M, Gooley TA, Myerson D, et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063-4071.
6. Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009; 113: 5711-5719.
7. Rubie H, Attal M, Campardou AM, et al. Risk factors for cytomegalovirus infection in BMT recipients transfused exclusively with seronegative blood products. Bone Marrow Transplant 1993; 11 (3): 209-214.
8. Bacigalupo A, Tedone E, Sanna MA, et al. CMV infections following allogeneic BMT: risk factors, early treatment and correlation with transplant related mortality. Haematologica 1992; 77 (6): 507-513.
9. Enright H, Haake R, Weisdorf D, et al. Cytomegalovirus pneumonia after bone marrow transplantation. Risk factors and response to therapy. Transplantation 1993; 55 (6): 1339-1346.
10. Boeckh M, Nichols G. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004; 103 (6): 2003-2008.
11. Lamba R, Carrum G, Myers GD, et al. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with alemtuzumab. Bone Marrow Transplant 2005; 36 (9): 797-802.
12. Kalpoe JS, van der Heiden PL, Vaessen N, Claas EC, Barge RM, Kroes AC. Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning. Bone Marrow Transplant 2007; 40 (2): 137-143.
13. Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo controlled, double-blind trial. Ann Intern Med 1993; 188: 179-184.
14. Winston DJ, Young JA, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo controlled, dose-ranging study. Blood 2008; 111 (11): 5403-5510.
15. Micklethwaite KP, Clancy L, Sandher U, et al. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood 2008; 112 (10): 3974-3981.
16. Miller W, Flynn P, McCullough J, et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. Blood 1986; 67 (4): 1162-1167.
17. Chakrabarti S, Milligan DW, Brown J, et al. Influence of cytomegalovirus (CMV) sero-positivity on CMV infection, lymphocyte recovery and non-CMV infections following T-cell-depleted allogeneic stem cell transplantation: a comparison between two T-cell depletion regimens. Bone Marrow Transplant 2004; 33 (2): 197-204.
18. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106 (8): 2912-2919.
19. Armand P, Kim HT, Cutler CS, et al. A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008; 14 (1): 28-35.
20. Passweg JR, Walker I, Sobocinski KA, Klein JP, Horowitz MM, Giralt SA; Chronic Leukemia Study Writing Committee of the International Bone Marrow Transplant Registry. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol 2004; 125 (5): 613-620.
21. Sormani MP, Oneto R, Bruno B, et al. A revised day +7 predictive score for transplant-related mortality: serum cholinesterase, total protein, blood urea nitrogen, gamma glutamyl transferase, donor type and cell dose. Bone Marrow Transplant 2003; 32 (2): 205-211.